Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180413498> ?p ?o ?g. }
- W3180413498 endingPage "345" @default.
- W3180413498 startingPage "339" @default.
- W3180413498 abstract "<h2>Abstract</h2> <b>Objectives:</b> To assess the efficiency and safety profiles of levetiracetam and (fos)phenytoin (phenytoin or fosphenytoin) for second-line treatment of seizures by performing a meta-analysis of RCTs. <b>Methods:</b> We systematically searched PubMed, Embase, Cochrane, FDA.gov, and ClinicalTrials.gov for RCTs (published before July 31, 2020; no language restrictions). Two independent reviewers screened abstracts and titles against inclusion and exclusion criteria published previously in the PROSPERO: CRD42020202736. Eleven studies fulfilled the established criteria. We assessed pooled data by using a random-effects model. Quality analysis was performed by using version 2 of the Cochrane risk-of-bias tool (RoB 2). RevMan v.5.3 was used to perform statistical analyses, and publication bias (egger's test) was assessed with Stata MP v.14.0. <b>Results:</b> Levetiracetam was similar to (fos)phenytoin in seizure termination rate (risk ratio [RR] 0.94; 95% CI 0.87 to 1.01), time of seizure termination (mean difference [MD] 0.44; -0.60 to 1.49), and drug resistance ([RR] 1.12, 0.86 to 1.45). The safety outcome showed a significant statistical difference between fosphenytoin group and levetiracetam group ([RR] 1.44, 1.14 to 1.81), while there was no significant difference observed between phenytoin treatment and levetiracetam treatment ([RR] 1.26, 0.99 to 1.60). <b>Conclusion:</b> Levetiracetam was similar to (fos)phenytoin in cessation rate convulsive status epilepticus, and drug resistance, while it was superior (fos)phenytoin in pooled safety outcome. Further exploration is still needed as to whether it is the first choice for second-line drugs." @default.
- W3180413498 created "2021-07-19" @default.
- W3180413498 creator A5001618242 @default.
- W3180413498 creator A5008676917 @default.
- W3180413498 creator A5024792434 @default.
- W3180413498 creator A5033259182 @default.
- W3180413498 creator A5061285043 @default.
- W3180413498 creator A5064511354 @default.
- W3180413498 creator A5071617219 @default.
- W3180413498 creator A5076367479 @default.
- W3180413498 creator A5087000080 @default.
- W3180413498 date "2021-10-01" @default.
- W3180413498 modified "2023-10-03" @default.
- W3180413498 title "Efficacy and safety of levetiracetam versus (fos)phenytoin for second-line treatment of epilepticus: a meta-analysis of latest randomized controlled trials" @default.
- W3180413498 cites W1514710752 @default.
- W3180413498 cites W1974809694 @default.
- W3180413498 cites W1975009255 @default.
- W3180413498 cites W1996896888 @default.
- W3180413498 cites W1996935441 @default.
- W3180413498 cites W2007774397 @default.
- W3180413498 cites W2014063191 @default.
- W3180413498 cites W2020743286 @default.
- W3180413498 cites W2021360813 @default.
- W3180413498 cites W2032049376 @default.
- W3180413498 cites W2036467957 @default.
- W3180413498 cites W2037281862 @default.
- W3180413498 cites W2061631865 @default.
- W3180413498 cites W2062404230 @default.
- W3180413498 cites W2069457036 @default.
- W3180413498 cites W2075455619 @default.
- W3180413498 cites W2077008944 @default.
- W3180413498 cites W2081154155 @default.
- W3180413498 cites W2084590756 @default.
- W3180413498 cites W2087191895 @default.
- W3180413498 cites W2094084354 @default.
- W3180413498 cites W2095163899 @default.
- W3180413498 cites W2101442317 @default.
- W3180413498 cites W2109887283 @default.
- W3180413498 cites W2115316843 @default.
- W3180413498 cites W2125435699 @default.
- W3180413498 cites W2138018801 @default.
- W3180413498 cites W2142181855 @default.
- W3180413498 cites W2142268315 @default.
- W3180413498 cites W2147050304 @default.
- W3180413498 cites W2151359410 @default.
- W3180413498 cites W2161470395 @default.
- W3180413498 cites W2164261965 @default.
- W3180413498 cites W2208053283 @default.
- W3180413498 cites W2252496421 @default.
- W3180413498 cites W2315431881 @default.
- W3180413498 cites W2409829112 @default.
- W3180413498 cites W2610306386 @default.
- W3180413498 cites W2621512652 @default.
- W3180413498 cites W2762775308 @default.
- W3180413498 cites W2777270043 @default.
- W3180413498 cites W2781176816 @default.
- W3180413498 cites W2785152374 @default.
- W3180413498 cites W2797434354 @default.
- W3180413498 cites W2884158372 @default.
- W3180413498 cites W2894022906 @default.
- W3180413498 cites W2923212435 @default.
- W3180413498 cites W2937512232 @default.
- W3180413498 cites W2938191513 @default.
- W3180413498 cites W2967618038 @default.
- W3180413498 cites W2982700315 @default.
- W3180413498 cites W2989624959 @default.
- W3180413498 cites W2990737153 @default.
- W3180413498 cites W2991266411 @default.
- W3180413498 cites W2993293913 @default.
- W3180413498 cites W3007993266 @default.
- W3180413498 cites W3011126394 @default.
- W3180413498 cites W3011352772 @default.
- W3180413498 cites W3012742050 @default.
- W3180413498 cites W3023970307 @default.
- W3180413498 cites W3034485957 @default.
- W3180413498 cites W4376848378 @default.
- W3180413498 cites W85213941 @default.
- W3180413498 doi "https://doi.org/10.1016/j.seizure.2021.07.012" @default.
- W3180413498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34284302" @default.
- W3180413498 hasPublicationYear "2021" @default.
- W3180413498 type Work @default.
- W3180413498 sameAs 3180413498 @default.
- W3180413498 citedByCount "9" @default.
- W3180413498 countsByYear W31804134982022 @default.
- W3180413498 countsByYear W31804134982023 @default.
- W3180413498 crossrefType "journal-article" @default.
- W3180413498 hasAuthorship W3180413498A5001618242 @default.
- W3180413498 hasAuthorship W3180413498A5008676917 @default.
- W3180413498 hasAuthorship W3180413498A5024792434 @default.
- W3180413498 hasAuthorship W3180413498A5033259182 @default.
- W3180413498 hasAuthorship W3180413498A5061285043 @default.
- W3180413498 hasAuthorship W3180413498A5064511354 @default.
- W3180413498 hasAuthorship W3180413498A5071617219 @default.
- W3180413498 hasAuthorship W3180413498A5076367479 @default.
- W3180413498 hasAuthorship W3180413498A5087000080 @default.
- W3180413498 hasBestOaLocation W31804134981 @default.
- W3180413498 hasConcept C118552586 @default.
- W3180413498 hasConcept C126322002 @default.